Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$INO Q3 '25 Earnings Results & Recap In Q3 2025, Inovio reported a net loss of $45.5 million (or $0.87 per share) driven by warrant liability adjustments and expects file acceptance by the FDA by year end for INO-3107 with a potential PDUFA date in mid-2026.
2

Since Post

Full Details
Top Replies
23Cazzy
They are burning through cash!
tomonota
Inovio's $(0.43) paper loss is for a mark to market accounting entry to reflect the outstanding warrants held, not a loss or expense recorded in net income; it is a market value based adjustment that will vanish as quickly as the accountant wrote it. No cash has been spent, expensed or lost; it's just the inability of the FASB accounting standards Board to recognize the variable market climate we find ourselves in- not a reason for me to sell, since our real loss was $(0.44) same a s last year. Without the influece of the short sellers it will be a gain of $0.43; wiping out the real loss related to our expenses invested to proote 3107 and d-PROTs.

Advertisement|Remove ads.